Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

52.56 +0.95 (+1.84%)

Official Closing Price Updated: 5:00 PM EST, Dec 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

99 100 Next >

Why Hims & Hers Stock Popped on Monday ↗

March 17, 2025

Morgan Stanley had great news for Hims & Hers stock today, so why didn't it upgrade the stock?

Via The Motley Fool

3 Unstoppable Stocks You Can Buy Now Without Any Hesitation ↗

March 17, 2025

Via The Motley Fool

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

March 15, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

CVS Weight Management Program Yields 15% Average Weight Loss, 26% Cost Saving Among Participants ↗

March 14, 2025

CVS Weight Management program members achieved 15% average weight loss, with 92% satisfaction and 26% lower GLP-1 medication costs for participating clients.

Via Benzinga

Why Novo Nordisk Stock Is Falling Today ↗

March 10, 2025

Via The Motley Fool

Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders ↗

March 14, 2025

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.

Via Benzinga

The Motley Fool's Market Volatility Toolkit ↗

March 13, 2025

Long-Term Perspective and Practical Steps for Uncertain Times

Via The Motley Fool

EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity ↗

March 13, 2025

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management. Top-line results are expected by mid-2025.

Via Benzinga

Lowey Dannenberg Notifies Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm

March 12, 2025

From Lowey Dannenberg, P.C.

Via GlobeNewswire

Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped ↗

March 12, 2025

Ignore the noise in GLP-1 stocks. Find the best value instead.

Via The Motley Fool

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion ↗

March 12, 2025

The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug.

Via Investor's Business Daily

NVO Shareholders Have an Opportunity to Lead the Class Action Against Novo Nordisk A/S – Contact Shareholder Rights Law Firm Robbins LLP for Information

March 11, 2025

From Robbins LLP

Via GlobeNewswire

Why Hims & Hers Health Stock Just Popped ↗

March 11, 2025

Via The Motley Fool

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

March 11, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Top 3 Health Care Stocks That May Keep You Up At Night In Q1 ↗

March 11, 2025

Via Benzinga

Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial ↗

March 11, 2025

Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.

Via Benzinga

These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy? ↗

March 11, 2025

Via The Motley Fool

Topics ETFs Stocks

Hims & Hers Stock Is Down 50% From Its High, but Is This a Buying Opportunity? ↗

March 11, 2025

Shutting down an acquisition caught investor attention, but there's more to the story.

Via The Motley Fool

Is Eli Lilly Stock a Buy? ↗

March 11, 2025

Via The Motley Fool

The State of Weight Loss Drugs ↗

March 10, 2025

Via The Motley Fool

Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors

March 10, 2025

Novo Nordisk slashed prices on its GLP-1 obesity drugs as it launches NovoCare to gain compounded GLP-1 users as the compounding labs face deadlines to cease.

Via MarketBeat

3 Cold Stocks That Can Bounce Back This Week ↗

March 10, 2025

These three stocks tumbled by at least 20% last week, but they may not be down for long.

Via The Motley Fool

Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand. ↗

March 10, 2025

Novo Nordisk's experimental obesity drug failed to top Eli Lilly's Zepbound. But there's something else that rattled investors.

Via Investor's Business Daily

Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 10, 2025

Via Benzinga

NOVO NORDISK A/S (NYSE: NVO) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline

March 10, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO

March 07, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - NVO

March 07, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Weight Loss Drugs Soar While Global Obesity Rates Climb, To Hit 50% Of Adults By 2050 Says New Report ↗

March 06, 2025

A global study shows obesity rates predicted to climb. Are weight loss drugs not doing enough or not available in enough countries?

Via Benzinga

Amgen Challenges Novo Nordisk's Ozempic And Eli Lilly's Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials ↗

March 06, 2025

Via Benzinga

Why Novo Nordisk Stock Outpaced the Market Today and Hims & Hers Lagged It ↗

March 05, 2025

Via The Motley Fool

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

All News about Novo Nordisk A/S Common Stock

Starting at $3.75/week.

Subscribe Today